Broad Institute Purchases Fluidigm Access Array™ System to Automate Sample Preparation for Targeted Resequencing

Fluidigm Corporation (NASDAQ:FLDM) today announced that the Broad Institute of MIT and Harvard has purchased an Access Array™ System to automate its sample preparation for targeted resequencing.

The Access Array System enhances the capabilities of powerful next-generation sequencing platforms by allowing the preparation of several sample libraries in parallel. The multiplexed Access Array sample prep system enables parallel amplification of 48 samples — the equivalent of 48 sequencing libraries — in a few hours. The system is used for target enrichment, sample barcoding for multiplexed sequencing, and sequencing library preparation using amplicon tagging.

“We expect our Access Array System’s ability to use very small amounts of sample and prepare libraries for amplicon-based resequencing to help The Broad with a number of important research projects,” said Gajus Worthington, Fluidigm President and Chief Executive Officer.

The Fluidigm Access Array System can be used with any PCR-based sample preparation method and with the reagents and primers of the customer’s choosing. Fluidigm offers Access Array Target-specific Primers as an easy way for customers to generate sequencer ready amplicons for next-generation sequencing. Currently, Fluidigm offers custom PCR-based primer design for human targeted resequencing. The Access Array System includes specific single-use microfluidic Integrated Fluidic Circuits (IFCs), two IFC Controllers, and a stand-alone thermal cycler to deliver results in just four hours.

About Fluidigm

Fluidigm (NASDAQ:FLDM) develops, manufactures and markets microfluidic systems for growth markets in the life science and agricultural biotechnology, or Ag-Bio, industries. Fluidigm’s proprietary microfluidic systems consist of instruments and consumables, including integrated fluidic circuits, or chips, and reagents. These systems are designed to significantly simplify experimental workflow, increase throughput and reduce costs, while providing the excellent data quality demanded by customers. Fluidigm actively markets three microfluidic systems including nine different commercial chips to leading pharmaceutical and biotechnology companies, academic institutions and Ag-Bio companies.

For more information, please visit www.fluidigm.com.

Fluidigm, the Fluidigm logo, BioMark, Access Array, Dynamic Array, Digital Array, FC1, TOPAZ, NanoFlex DELTAgene and SNPtype are trademarks or registered trademarks of Fluidigm Corporation

Cautionary Note About Forward-Looking Statements

This press release contains forward-looking statements within the meaning of United States federal securities laws. Forward-looking statements include, among others, statements relating to the anticipated performance of our products and any implied statements concerning our future operating performance. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results. Factors that could materially affect future results include, but are not limited to, risks relating to market acceptance and performance of our products, the potential for quarterly variations in our operating results, variability in our sales cycle, and our ability to successfully launch new products and applications. Information on these and additional risks and uncertainties that could affect Fluidigm’s business and operating results are contained in Fluidigm’s most recent Quarterly Report on Form 10-Qs and its other filings with the Securities and Exchange Commission. These forward- looking statements speak only as of the date hereof. Fluidigm Corporation disclaims any obligation to update these forward-looking statements.